The European Commission (EC) has granted marketing authorisation for Averoa's oral therapy Xoanacyl for chronic kidney ...

A research team from the School of Clinical Medicine of the LKS Faculty of Medicine of the University of Hong Kong (HKUMed) ...

XOANACYL is an oral therapy designed to address critical challenges in CKD, including Iron deficiency and hyperphosphatemia ; Averoa submitted XOANACYL for UK approval via MHRA’ ...

Skepticism still persists around the use of measurable residual disease (MRD) for clinical and regulatory decision-making in ...

FDA approves new Brukinsa tablet for five blood cancers, offering simpler dosing with the same safety and effectiveness as ...

Ilunocitinib tablets are currently available in Brazil, Canada and Japan, in addition to the US. Elanco noted that, once the ...

GSK has applied to the European Medicines Agency to expand use of its respiratory syncytial virus (RSV) vaccine to adults ...

BeOne Medicines (NASDAQ:ONC) gains FDA approval for a new tablet version of Brukinsa, simplifying dosage for patients.

The latest update atopic dermatitis guidelines include the new approval of lebrikizumab and the expanded use of baricitinib ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

Patients taking weight-loss medicines such as Novo Nordisk A/S’s Ozempic and Wegovy are at risk of developing an eye ...

today announces that it has been granted Orphan Drug Designation in Europe by the European Medicines Agency (EMA) for its lead product QRX003 in Netherton Syndrome. Orphan Drug Designation in ...